1887

Abstract

Binding to heparin of hepatitis C virus (HCV) and hepatitis B virus (HBV) from chronic carriers was investigated. Eighty per cent of HCV RNA from an agammaglobulinaemic patient (IgG-free virus) was retained on immobilized heparin and eluted with ⩾0·4 M NaCl, in contrast to ∼20 % from immunocompetent chronic carriers (with ⩽8 % IgG-free virus). Increased binding to heparin of the HCV fraction that was not retained by a protein G column suggested that antibodies complexed to the virions partially inhibited the interaction. A higher proportion (15–80 %) of HBV from chronic carriers bound to heparin and eluted with ⩾0·4 M NaCl. After washing of the heparin columns with 0·3 M NaCl, <1 % of total plasma proteins co-eluted with HCV or HBV. By this one-step heparin chromatography, without ultracentrifugation, IgG-free HCV and IgG-free HBV were preferentially purified from human plasma by 1000-fold and greater than 500-fold, respectively. Following assessment with an anti-E2 envelope protein antibody, the amount of immunoprecipitated HCV particles after heparin purification was similar to that in the original plasma, suggesting that undamaged virions were purified. This was further supported by heparin-purified HCV binding to lymphocyte cell lines in a dose-dependent manner. Intact HBV particles were detected by electron microscopy. It was concluded that HCV and HBV from chronically infected patients bind to heparin, the closest homologue of liver heparan sulfate, and that heparin chromatography is an efficient and gentle method for purifying these viruses from human plasma. In the absence of cell-culture systems or alternative robust purification methods, heparin chromatography may help greatly in binding and infectivity studies.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80614-0
2005-03-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/3/vir860677.html?itemId=/content/journal/jgv/10.1099/vir.0.80614-0&mimeType=html&fmt=ahah

References

  1. André P., Komurian-Pradel F., Deforges S. 7 other authors 2002; Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 76:6919–6928 [CrossRef]
    [Google Scholar]
  2. Barth H., Schäfer C., Adah M. I. 10 other authors 2003; Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278:41003–41012 [CrossRef]
    [Google Scholar]
  3. Byrnes A. P., Griffin D. E. 1998; Binding of Sindbis virus to cell surface heparan sulfate. J Virol 72:7349–7356
    [Google Scholar]
  4. Candotti D., Temple J., Owusu-Ofori S., Allain J.-P. 2004; Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. J Virol Methods 118:39–47 [CrossRef]
    [Google Scholar]
  5. Chen Y., Maguire T., Hileman R. E., Fromm J. R., Esko J. D., Linhardt R. J., Marks R. M. 1997; Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3:866–871 [CrossRef]
    [Google Scholar]
  6. Choo S.-H., So H.-S., Cho J. M., Ryu W.-S. 1995; Association of hepatitis C virus particles with immunoglobulin: a mechanism for persistent infection. J Gen Virol 76:2337–2341 [CrossRef]
    [Google Scholar]
  7. Clayton R. F., Owsianka A., Aitken J., Graham S., Bhella D., Patel A. H. 2002; Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol 76:7672–7682 [CrossRef]
    [Google Scholar]
  8. Cribier B., Schmitt C., Kirn A., Stoll-Keller F. 1998; Inhibition of hepatitis C virus adsorption to peripheral blood mononuclear cells by dextran sulfate. Arch Virol 143:375–379 [CrossRef]
    [Google Scholar]
  9. Einarsson M., Kaplan L., Utter G. 1978; Purification of hepatitis B surface antigen by affinity chromatography. Vox Sang 35:224–233 [CrossRef]
    [Google Scholar]
  10. Fujita N., Kaito M., Ishida S., Nakagawa N., Ikoma J., Adachi Y., Watanabe S. 2001; Paraformaldehyde protects of hepatitis C virus particles during ultracentrifugation. J Med Virol 63:108–116 [CrossRef]
    [Google Scholar]
  11. Garson J. A., Lubach D., Passas J., Whitby K., Grant P. R. 1999; Suramin blocks hepatitis C binding to human hepatoma cells in vitro. J Med Virol 57:238–242 [CrossRef]
    [Google Scholar]
  12. Germi R., Crance J.-M., Garin D., Guimet J., Lortat-Jacob H., Ruigrok R. W. H., Zarski J.-P., Drouet E. 2002a; Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 68:206–215 [CrossRef]
    [Google Scholar]
  13. Germi R., Crance J.-M., Garin D., Guimet J., Lortat-Jacob H., Ruigrok R. W. H., Zarski J.-P., Drouet E. 2002b; Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 292:162–168 [CrossRef]
    [Google Scholar]
  14. Hamaia S., Li C., Allain J.-P. 2001; The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood 98:2293–2300 [CrossRef]
    [Google Scholar]
  15. Hijikata M., Shimizu Y. K., Kato H., Iwamoto A., Shih J. W., Alter H. J., Purcell R. H., Yoshikura H. 1993; Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 67:1953–1958
    [Google Scholar]
  16. Hileman R. E., Fromm J. R., Weiler J. M., Linhardt R. J. 1998; Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20:156–167 [CrossRef]
    [Google Scholar]
  17. Hilgard P., Stockert R. 2000; Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology 32:1069–1077 [CrossRef]
    [Google Scholar]
  18. Hulst M. M., van Gennip H. G. P., Vlot A. C., Schooten E., de Smit A. J., Moormann R. J. M. 2001; Interaction of classical swine fever virus with membrane-associated heparan sulfate: role for virus replication in vivo and virulence. J Virol 75:9585–9595 [CrossRef]
    [Google Scholar]
  19. Ishii K., Rosa D., Watanabe Y. 9 other authors 1998; High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28:1117–1120 [CrossRef]
    [Google Scholar]
  20. Kanto T., Hayashi N., Takehara T., Hagiwara H., Mita E., Naito M., Kasahara A., Fusamoto H., Kamada T. 1995; Density analysis of hepatitis C virus particle population in the circulation of infected hosts: implications for virus neutralization or persistence. J Hepatol 22:440–448 [CrossRef]
    [Google Scholar]
  21. Kjellen L., Lindahl U. 1991; Proteoglycans: structures and interactions. Annu Rev Biochem 60:443–475 [CrossRef]
    [Google Scholar]
  22. Lyon M., Deakin J. A., Gallagher J. T. 1994; Liver heparan sulfate structure: a novel molecular design. J Biol Chem 269:11208–11215
    [Google Scholar]
  23. Margolis H. S., Alter M. J., Hadler S. C. 1997 Viral hepatitis. In Viral Infections of Humans: Epidemiology and Control , 4th edn. Edited by Evans A. S., Kaslow R. A. New York: Plenum Publishing;
    [Google Scholar]
  24. Patel M., Yanagishita M., Roderiquez G., Bou-Habib D. C., Oravecz T., Hascall V. C., Norcross M. A. 1993; Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res Hum Retrovir 9:167–174 [CrossRef]
    [Google Scholar]
  25. Pileri P., Uematsu Y., Campagnoli S. 8 other authors 1998; Binding of hepatitis C virus to CD81. Science 282:938–941 [CrossRef]
    [Google Scholar]
  26. Rabenstein D. L. 2002; Heparin and heparan sulfate: structure and function. Nat Prod Rep 19:312–331 [CrossRef]
    [Google Scholar]
  27. Shieh M.-T., WuDunn D., Montgomery R. I., Esko J. D., Spear P. G. 1992; Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol 116:1273–1281 [CrossRef]
    [Google Scholar]
  28. Shukla D., Liu J., Blaiklock P. 7 other authors 1999; A novel role for 3- O -sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 99:13–22 [CrossRef]
    [Google Scholar]
  29. Su C.-M., Liao C.-L., Lee Y.-L., Lin Y.-L. 2001; Highly sulfated forms of heparin sulfate are involved in Japanese encephalitis virus infection. Virology 286:206–215 [CrossRef]
    [Google Scholar]
  30. Summerford C., Samulski R. J. 1998; Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72:1438–1445
    [Google Scholar]
  31. Tajima Y., Nagumo F., Nishimura T., Tadano J. 1992; Phosphotungstate as a useful eluent for hepatitis-B virus surface antigen purification by heparin-sepharose affinity chromatography. Biomed Chromatogr 6:72–76 [CrossRef]
    [Google Scholar]
  32. Trestard A., Bacq Y., Buzelay L., Dubois F., Barin F., Goudeau A., Roingeard P. 1998; Ultrastructural and physicochemical characterization of the hepatitis C virus recovered from the serum of an agammaglobulinemic patient. Arch Virol 143:2241–2245 [CrossRef]
    [Google Scholar]
  33. Tsai J.-F., Jeng J.-E., Chang W.-Y., Ho M.-S., Lin Z.-Y., Tsai J.-H. 1995; Circulating immune complexes in chronic hepatitis C. J Med Virol 46:12–17 [CrossRef]
    [Google Scholar]
  34. Wellnitz S., Klumpp B., Barth H., Ito S., Depla E., Dubuisson J., Blum H. E., Baumert T. F. 2002; Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol 76:1181–1193 [CrossRef]
    [Google Scholar]
  35. Wünschmann S., Medh J. D., Klinzmann D., Schmidt W. N., Stapleton J. T. 2000; Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 74:10055–10062 [CrossRef]
    [Google Scholar]
  36. Xiang J., Klinzman D., McLinden J., Schmidt W. N., LaBrecque D. R., Gish R., Stapleton J. T. 1998; Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. J Virol 72:2738–2744
    [Google Scholar]
  37. Ying C., van Pelt J. F., Van Lommel A., Van Ranst M., Leyssen P., De Clercq E., Neyts J. 2002; Sulphated and sulphonated polymers inhibit the initial interaction of hepatitis B virus with hepatocytes. Antivir Chem Chemother 13:157–164 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80614-0
Loading
/content/journal/jgv/10.1099/vir.0.80614-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error